Venus Remedies gets marketing authorization from Saudi Arabia for chemotherapy drug Docetaxel
The development comes three months after the company received good manufacturing practices (GMP) certification from the Saudi Food and Drug Authority (SFDA) for all its production facilities at its unit in Baddi, Himachal Pradesh.
VENUS REMEDIES LTD. - 526953 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Venus Remedies consolidates its position in oncology space with Saudi marketing approval for Docetaxel. VENUS REMEDIES LTD. - 526953 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed herewith newspaper publication of Financial Results for the quarter and year ended on 31st March 2023. VENUS REMEDIES LTD. - 526953 - Announcement under Regulation 30 (LODR)-Change in Directorate
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), we wish to inform you that based on the recommendation of Nomination and Remuneration Committee, the Board of Directors have appointed Mr. NPS Monga as an Additional Director (Non- Executive Independent Director) w.e.f. 29th May 2023 to hold office till the conclusion of the next General Meeting and will be appointed as regular Non -Executive Independent Director for five consecutive years, subject to approval of members in the next general meeting.
Venus Remedies hits 20% upper circuit after March quarter net profit jumps 200%
Standalone net profit for the March quarter stood at Rs 7.54 crore, up 211.57 percent from Rs 2.42 crore a year ago. Revenue for the quarter rose 15.34 percent to Rs 148.53 crore last year. VENUS REMEDIES LTD. - 526953 - Financial Results As On 31.03.2023
Financial results as on 31.03.2023 VENUS REMEDIES LTD. - 526953 - Board Meeting Outcome for Outcome Of Board Meeting
Audited Financial Results for the quarter and year ended on 31st March 2023 along with Limited Review report. 2. the appointment Mr. NPS Monga as an Additional Director (Non- Executive Independent Director) w.e.f. 29th May 2023 to hold office till the conclusion of the next General Meeting of the Company and will be appointed as regular Independent Non -Executive Director for five consecutive years, subject to approval of members in the next General Meeting. VENUS REMEDIES LTD. - 526953 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Venus Remedies secures Kenyan GMP certification for all its manufacturing facilities in Baddi.
Venus Remedies gets GMP certification from Kenya for production facilities in Baddi
The Pharmacy and Poisons Board (PPB) of the Kenyan Health Ministry granted the certification following a rigorous audit of the company's production facilities in Baddi, a company statement said.